Dec 3 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK:
A SELECTIVE 5-HT2A RECEPTOR AGONIST (SYH2056 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN U.S.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.